Business Wire

Advance Auto Parts, Blue Cross NC, Emory Healthcare, Johnsonville, Parkview Health, and Royal Bank of Scotland Receive Planview Vision Awards

13.11.2019 19:01:00 EET | Business Wire | Press release

Share

Over 700 attendees came together at Planview Horizons 2019 to connect, collaborate, and celebrate with their industry peers. This year, Advance Auto Parts, Blue Cross NC, Emory Healthcare, Johnsonville, Parkview Health, and Royal Bank of Scotland were the recipients of Planview Vision Awards for transformational leadership and excellence.

“There are many remarkable business transformation journeys that our customers have undertaken leveraging Planview solutions,” said Marc Cannon, Planview chief customer officer. “We were honored at this year’s Planview Horizons to celebrate these six visionary organizations for their commitment to, and success in, achieving their strategic goals.”

Advance Auto Parts

To address the industry trends around increased use of ridesharing, electric cars, and autonomous vehicles, a few “hidden innovators” at Advance Auto Parts set out to generate and collaborate on new ideas that would disrupt the market and delight their customers. With Planview Spigit™, Advance Auto Parts is successfully driving a culture of innovation.

Blue Cross NC

Blue Cross NC is shifting to a product-centric approach, utilizing continuous planning and delivery to achieve their mission: improving the health and well-being of customers. By leveraging Planview solutions, the organization is moving toward transformation, igniting innovation, and driving agility for relentless execution, all essential to realizing their strategy and vision.

Emory Healthcare

Being unable to forecast three weeks out or answer executives’ questions created an opportunity for Emory Healthcare to implement a solution for work intake, workflow management, and collaboration. The combination of Planview PPM Pro™ and Planview LeanKit™ allows Emory Healthcare to tell a collective story of status, flow, delivery, and alignment to strategy.

Johnsonville

Johnsonville recognizes that no matter how teams work, all goals and processes need to be measurable and reportable to ultimately deliver results. Johnsonville utilizes Planview Enterprise One™ and Planview Projectplace™ across the organization to enable collaboration that drives efficiency and innovation in making great tasting, high-quality products craved around the globe.

Parkview Health

Leveraging strategic work intake to prioritize projects within Planview PPM Pro has given Parkview Health the ability to identify investments that align with the organization’s strategic intent. Working with senior leaders, the EPPM team has helped prioritize and optimize capital spend. In addition, Parkview Health has seen increased productivity and collaboration with the rollout of Planview Projectplace across multiple business lines.

Royal Bank of Scotland

Royal Bank of Scotland (RBS) is shifting its approach toward investments and faster delivery to become a Lean enterprise by using the SAFe model. RBS evolved its use of Planview solutions to move from standard PPM processes and frameworks to embrace an agility-centric mindset, establish programs as key strategic vehicles to achieve outcomes and benefits, and discover new ways of working to realize a scaled Agile transformation. View this webcast to learn more.

About Planview

There is a bold new way of working, where every individual and team can move seamlessly from strategy to successful delivery – every day. Planview makes it possible. We provide the industry’s best and most comprehensive solutions designed for strategic planning, portfolio and resource management, Lean and Agile delivery, product portfolio management, capability and technology management, innovation management, and collaborative work management. Imagine realizing Agile at scale, creating a culture of innovation, and making the product shift. You are a change agent. So are we. For more information, visit www.planview.com.

Planview® and Planview Horizons® are registered trademarks of Planview, Inc.

All other trademarks listed herein are owned by their respective companies.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Planview
Karoline McLaughlin
kmclaughlin@planview.com
+1 512 596 3493

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye